Josep M. Piulats - Concepedia

Author

Josep M. Piulats

Also Known As

A. Arance, J M Piulats, J Piulats, J. M. Piulats, J. Piulats, J.M. Piulats, JM Piulats, Johann De Bono, Jose M. Piulats, Jose Maria Piulats

420

Publications

14.3K

Citations

H-Index

Concepts

All Affiliations

Institut Català d'Oncologia Institut d'Investigació Biomédica de Bellvitge Bellvitge University Hospital Centro de Investigación Biomédica en Red de Cáncer Institut Català d'Ornitologia

About

Josep M. Piulats is an author at Institut Català d'Oncologia specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	37	2.9K
2	Cell Biology	9	9	490
3	Health Sciences	8	8	223
4	Diagnostic Sciences	4	4	122
5	Cellular Therapies	1	1	132

Josep M. Piulats

Publications

12K

Citations

H-Index

Page 1

	Year	Citations
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, New England Journal of Medicine	2012	2.8K
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, New England Journal of Medicine	2021	806
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Journal of Clinical Oncology PharmacotherapyImmunotherapeuticsImmunotherapyMinimally Symptomatic PatientsPhase Iii Trial	2016	742
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Journal of Clinical Oncology	2019	679
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration Wassim Abida, Akash Patnaik, David Campbell, Journal of Clinical Oncology	2020	655
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations David Tamborero, Carlota Rubio-Pérez, Ferran Muiños, Clinical Cancer Research	2018	411
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial Matthew R. Smith, Chris Parker, Fred Saad, The Lancet Oncology Era 223UrologyMedicineClinical TrialsPharmacotherapy	2019	383
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer Karim Fizazi, Josep M. Piulats, M. Neil Reaume, New England Journal of Medicine	2023	380
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Elena Castro, Nuria Romero-Laorden, Ángela del Pozo, Journal of Clinical Oncology	2019	366
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Alain P. Algazi, Katy K. Tsai, Alexander N. Shoushtari, Cancer	2016	362

Page 1